Vividion Therapeutics
Clinical-stage biopharmaceutical company using a covalent-first chemoproteomics discovery platform to identify ligandable pockets across the human proteome and develop selective small-molecule therapeutics for oncology and immunology. Operates an industrialized screening engine, a large covalent fragment library, integrated multi-omic data systems for proteomics/genetics/structural biology, and global clinical development programs.
Industries
Nr. of Employees
large (251-1000)
Vividion Therapeutics
Patents
Products
Oral WRN inhibitor — clinical program
Covalent small-molecule inhibitor targeting WRN dependency in MSI-high/dMMR tumors; progressed through discovery and preclinical models into Phase I/IB and Phase II clinical trials.
KEAP1 activator — clinical program
Small molecule that allosterically modulates KEAP1 to promote degradation of NRF2; progressed from preclinical validation into Phase I clinical evaluation.
Inhibitors of RAS–PI3Kα interaction — clinical program
Covalent small molecules that disrupt RAS-dependent activation of PI3Kα (PIK3CA) with demonstrated preclinical tumor growth inhibition and progression to Phase I clinical evaluation.
Multiple undisclosed early-stage discovery programs
Platform-driven discovery and preclinical-stage small-molecule programs in oncology and immunology identified via chemoproteomics and covalent chemistry approaches.
VVD-037
A highly selective, first-in-class small molecule activator of KEAP1 that allosterically enhances the ability of this E3 ligase to degrade its natural cellular target, NRF2, to inhibit tumor growth in NRF2-hyperactivated solid tumors.
VVD-642
A small molecule RAS-PIK3CA inhibitor that specifically blocks the interaction between RAS and PIK3CA to inhibit oncogenic signaling without disrupting homeostatic signaling.
Oral WRN inhibitor — clinical program
Covalent small-molecule inhibitor targeting WRN dependency in MSI-high/dMMR tumors; progressed through discovery and preclinical models into Phase I/IB and Phase II clinical trials.
KEAP1 activator — clinical program
Small molecule that allosterically modulates KEAP1 to promote degradation of NRF2; progressed from preclinical validation into Phase I clinical evaluation.
Inhibitors of RAS–PI3Kα interaction — clinical program
Covalent small molecules that disrupt RAS-dependent activation of PI3Kα (PIK3CA) with demonstrated preclinical tumor growth inhibition and progression to Phase I clinical evaluation.
Multiple undisclosed early-stage discovery programs
Platform-driven discovery and preclinical-stage small-molecule programs in oncology and immunology identified via chemoproteomics and covalent chemistry approaches.
VVD-037
A highly selective, first-in-class small molecule activator of KEAP1 that allosterically enhances the ability of this E3 ligase to degrade its natural cellular target, NRF2, to inhibit tumor growth in NRF2-hyperactivated solid tumors.
VVD-642
A small molecule RAS-PIK3CA inhibitor that specifically blocks the interaction between RAS and PIK3CA to inhibit oncogenic signaling without disrupting homeostatic signaling.
Expertise Areas
- Chemoproteomics-driven drug discovery
- Covalent small-molecule discovery
- Medicinal chemistry and SAR optimization
- Preclinical pharmacology and translational in vivo models
Key Technologies
- Chemoproteomics
- Covalent fragment libraries
- High-resolution high-throughput mass spectrometry
- Integrated proteomics–genetics–structural data integration
News & Updates
Announcement that the head of R&D assumed the role of President and Chief Executive Officer and joined the Board; prior CEO transitioned to Chairman of the Board.
Announcement of a new Chief Medical Officer joining the company to lead clinical development and translational strategy.
Collaboration agreement to discover targets and co-develop targeted oncology programs, including option/rights terms for multiple programs.
Description of an 'arm's-length' operating model that preserves independent R&D while leveraging resources from a parent pharmaceutical company and notes site expansion to support growth.
Announcement of a scientific advisory board composed of external leaders in chemical biology, oncology, immunology and drug discovery to advise on research and development strategy.
Manuscript describing discovery and optimization of a covalent allosteric WRN inhibitor and its selection for clinical development.
Announcement that the head of R&D assumed the role of President and Chief Executive Officer and joined the Board; prior CEO transitioned to Chairman of the Board.
Announcement of a new Chief Medical Officer joining the company to lead clinical development and translational strategy.
Collaboration agreement to discover targets and co-develop targeted oncology programs, including option/rights terms for multiple programs.
Description of an 'arm's-length' operating model that preserves independent R&D while leveraging resources from a parent pharmaceutical company and notes site expansion to support growth.
Announcement of a scientific advisory board composed of external leaders in chemical biology, oncology, immunology and drug discovery to advise on research and development strategy.
Manuscript describing discovery and optimization of a covalent allosteric WRN inhibitor and its selection for clinical development.